Total lesions on MRI at 48 hours

Slides:



Advertisements
Similar presentations
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Advertisements

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.
Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Embolic Protection Devices in Transcatheter Aortic Valve Replacement: Are We Barking Up the Wrong Vascular Tree? Circulation: cardiovascular intervention.
(p for noninferiority = 0.01)
TriGuard Device for Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Multicenter Real-World Experience Masieh Abawi, Ermela.
Trans- catheter aortic valve replacement vs
The American College of Cardiology Presented by Dr. Adnan Kastrati
Preventive Role of Embolic Protection Devices:
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Heart Valve Thrombosis & Neuro-Outcomes
Claret Cerebral Protection Device: Implications of the Sentinel Study
Stroke After TAVR: Surgeon View
CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo.
Devices for Stroke Prevention
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Protection Devices in Stroke Prevention
Pravastatin in Elderly Individuals at Risk of Vascular Disease
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
Presented by Dr. Leif Thuesen
LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.
Angiography-guided PCI
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
Primary endpoint at 1 year
EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.
Median total new lesion volume
PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.
CoreValve US Pivotal Trial High-Risk Arm Device and Access Routes.
How to Optimize TAVR Outcomes
TAVR and the Risk of Thrombosis
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.
Alexander Ghanem et al. JACC 2010;55:
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.
BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.
ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.
ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome)
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.
American Heart Association Presented by Dr. Julinda Mehilli
Main branch restenosis at 1 year
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
(p < for noninferiority)
BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.
Ezetimibe/simvastatin
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Impedence-guided management
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Ischemic Postconditioning
ARISE Trial Aggressive Reduction of Inflammation Stops Events
BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Remote ischemic preconditioning
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,
Primary safety endpoint
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
(p for noninferiority = 0.01)
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Presentation transcript:

Total lesions on MRI at 48 hours CLEAN-TAVI Trial design: Patients undergoing TAVR were randomized in 1:1 fashion to receive either a cerebral embolic protection device (CEPD), Claret-Montage, or routine management during the procedure. Patients were followed for 7 days. Results (p = 0.0023) At 2 days, there was a significant reduction in the total number of lesions on MRI in the CEPD vs. no filter arms: 8 vs. 16, p = 0.0023 Similar results were noted on 7-day MRI: 5 vs. 10, p = 0.012 Clinical strokes were similar No. of lesions Conclusions Embolic protection with Claret-Montage CEPD results in fewer cerebral embolic events vs. routine management using no filter in transfemoral TAVR; results are interesting given the high cerebral embolism rate in TAVR patients Further studies powered for clinical endpoints in TAVR patients are necessary Total lesions on MRI at 48 hours CEPD (n = 50) No filter (n = 50) Presented by Dr. Axel Linke at TCT 2014